47.77
+0.6(+1.27%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
315
First IPO Date
May 25, 2018
| Name | Title | Pay | Year Born |
| Sanj K. Patel | Chief Executive Officer & Chairman of the Board | 1.64M | 1969 |
| Mark Ragosa | Senior VP & CFO | 800,778 | 1974 |
| Ross Michael Moat | Executive Vice President and Chief Corporate & Commercial Officer | 809,776 | 1980 |
| Eben Tessari | Executive VP & COO | 818,644 | 1982 |
| John F. Paolini | Executive VP & Chief Medical Officer | 893,755 | 1965 |
| Jonathan Kirshenbaum | Investor Relations Officer | 0 | N/A |
| Douglas Barry | Senior Vice President, Chief Legal Officer & Secretary | 0 | N/A |
| Michael R. Megna | Senior VP & Chief Accounting Officer | 0 | 1971 |
| Megan Woods | Senior VP & Chief Human Resources Officer | 0 | N/A |
| Mei Jang | Senior Vice President of Technical Operations | 0 | N/A |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.